MedTrace Logo

Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance

NCT01862757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2017-07-02

No results posted yet for this study

Summary

Background:

\- Some people who are obese may have decreased muscle strength. They may have greater muscle mass shown in scans, but they show poor results in exercise tests. Poor muscle strength might cause some of the difficulty with exercise performance. Researchers want to test muscle strength in the arms and legs of overweight women. They will also see how insulin resistance affects muscle strength in these women.

Objectives:

* To test muscle strength in overweight women.
* To see if insulin resistance affects muscle strength.

Eligibility:

\- Women at least 18 years of age who are overweight (body mass index greater than 25 kg/m2).

Design:

* Participants will be asked to fast before having an initial blood test to measure glucose and insulin levels.
* On a different day, they will have the strength testing. The first test will measure leg muscle strength by testing the quadriceps and the hamstrings. The second test will measure arm muscle strength by testing the biceps and triceps. The final test will measure hand muscle (grip) strength.
* All the tests should take about an hour.

Conditions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Richard O Cannon, M.D. · National Heart, Lung, and Blood Institute (NHLBI)

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-06
Primary Completion
2013-06-14
Completion
2015-03-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01862757 on ClinicalTrials.gov